ProQR Therapeutics N.V

+0.07 (+0.90%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)509.26M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.27 Million
Adjusted EPS-$0.24
See more estimates
10-Day MA$7.82
50-Day MA$7.19
200-Day MA$6.13
See more pivots

ProQR Therapeutics N.V Stock, NASDAQ:PRQR

Zernikedreef 9, Leiden, Zuid-Holland 2333 CK
Phone: +
Number of Employees: 150.4


ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.